Phase 2 N=53 Neuroactive Steroids and Traumatic Brain Injury (TBI) in OEF/OIF Veterans
Brain Injuries, Traumatic
Primary: CAPS (Cluster D Symptoms) - PRIMARY BEHAVIORAL OUTCOME MEASURE — 13.88; 12.89; 11.23; 10.89 Score
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=21 Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia
Severe Thalassemia
Primary: Primary Objective: Event-free Survival at 1 Year. — 17 Participants
Phase 3 N=84 Liposomal Bupivacaine With Bupivacaine in Ankle Fracture Open Reduction Internal Fixation (ORIF)
Ankle Fracture
Primary: Pain Levels on a Visual Analog Scale ( VAS) — 7.05; 4.03; 7.49; 6.60 units on a scale — p=<0.10
Phase 2 N=4 Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)
Lymphoma · Primary Central Nervous System Lymphoma · Recurrent/Refractory Secondary Central Nervous System Lymphoma
Primary: Progression Free Survival — 39 days
Phase 3 N=76 Open-Label Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Acute Pain
Moderate-to-severe Acute Pain
Primary: Time-weighted Summed Pain Intensity Difference (SPID) Over the 1-hour (SPID1). — 2.11 units on a scale
N/A N=463 Group Learning Achieves Decreased Incidents of Lower Urinary Symptoms
Urinary Incontinence, Stress · Urinary Incontinence, Urge
Primary: Group Behavioral Treatment Effectiveness as Shown by Changes From Baseline to 3 Months in Urinary Incontinence Severity. — -2; -1 units on a scale
Phase 3 N=414 Comparison of GSK Biologicals' Meningococcal Vaccine (GSK134612) and Licensed MenC-CRM197 Vaccine in Healthy Children
Infections, Meningococcal
Primary: Number of Subjects With Vaccine Response to Meningococcal Serogroup C Serum Based on a Bactericidal Assay Using Baby Rabbit Complement (rSBA-MenC) Antibody — 254; 88…
N/A N=11 Impact of Xenazine(Tetrabenazine)on Gait and Functional Activity in Individuals With Huntington's Disease
Huntington's Disease
Primary: Tinetti Mobility Test Score — 19.91; 17.09 Total Tinetti Mobility Test Score (TMT)
N/A N=111 Effects of Continuous Positive Airway Pressure (CPAP) on Glucose Metabolism
Obstructive Sleep Apnea · Sleep Apnea · Sleep-disordered Breathing
Primary: Insulin Sensitivity (SI) — 1.95; 2.22 [mU/L]^-1 x [min]^-1
Phase 4 N=205 Mirvaso in Use Study
Rosacea
Primary: Pre-Treatment Clinician Erythema Assessment (CEA) — 0; 0; 7; 144 Participants
Phase 3 N=25 Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' IPV Vaccine (PoliorixTM) in Toddlers
Poliomyelitis
Primary: Number of Subjects With Any and Grade 3 Solicited Local Symptoms — 4; 0; 5; 0 Subjects
Phase 2 N=13 Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia
Severe Aplastic Anemia · Very Severe Aplastic Anemia · Moderate Aplastic Anemia
Primary: Proportion of Participants With Platelet Response — 0.23 proportion of participants
Phase 2 N=50 Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities · Adult Acute Myeloid Leukemia With Del(5q) · Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Primary: Rates of Complete Remission and Complete Remission With Incomplete Recovery of Counts — 38; 33; 41; 23 Participants
Phase 3 N=837 A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis
Psoriasis
Primary: Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) in the Guselkumab Group Compared to the Placebo…
Phase 4 N=190 MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.
Rosacea
Primary: Efficacy Variable: Percentage of Patients Defined as Success on the Global Rosacea Severity Grading Scale Called Investigator's Global Assessment (IGA): — 53; 35…